Canine Stem Cell Conditioned Media Accelerates Epithelial Migration in the Canine Tympanic Membrane.
Suh H., Kim S., Oh T., Bae S.
Laboratory Study, published in Vet Sci (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Vet Sci (2022)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35202322
- PMCID
- PMC8876637
- DOI
- 10.3390/vetsci9020069
- Citations
- 3
Abstract (original English)
Similar to skin, epithelia in the tympanic membrane (TM) regenerate and move toward the opening of the external ear canal, a process called epithelial migration (EM). EM is important for maintaining healthy ears because this process removes cerumen and debris. Therefore, increasing the rate of EM or TM regeneration could be very important for healthy ear maintenance and function. Stem cells or their conditioned media have been used in medical therapy in humans to increase the rate and efficacy of EM. The purpose of this study was to evaluate the ability of canine stem cell conditioned media to accelerate EM in canine TMs. Canine adipose tissue derived-mesenchymal stem cell conditioned media (cAD-MSCCM), and several cytokines related to keratinocyte growth or migration within the media were quantified using ELISA. Ink drops were placed on the TMs of four normal beagles. Then, cAD-MSCCM was applied weekly, a total of three times to the TMs of one ear, and nothing was applied to the other eye. The results showed a higher TM EM rate in the treatment group than in the control group ( p < 0.05). No adverse events were recorded. These results suggest that the weekly application of cAD-MSCCM accelerates the TM EM rate.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.